RxDoctor Payments DataLook up a doctor →

Maria Mascolo, MD

Pulmonary Disease · Rincon, GANPI 1194793042

Payments from drug & device makers

$2,665,458in general payments, 2019–2025

Across 2,169 payments — averaging $1228.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$551K
  • Sanofi Pasteur Inc.$542K
  • Pfizer$373K
  • Insmed, Inc.$294K
  • GSK$205K
  • Jazz Pharmaceuticals Inc.$196K
  • plus $506K from 42 others

What the payments were for

  • Consulting fees$16,2775%
  • Speaking & faculty fees$276,57577%
  • Travel & lodging$37,96311%
  • Food & beverage$27,0118%
  • Education$2180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,665,458 in reported general payments places this provider in the 95th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$343,908
Medicare patients
800
Services billed
5,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter338$319,318
Prolastin CAlpha-1-Proteinase Inhibitor15$189,194
Breztri AerosphereBudesonide/Glycopyr/Formoterol112$101,270
Fasenra PenBenralizumab13$74,212
Breo ElliptaFluticasone/Vilanterol88$53,988
NucalaMepolizumab12$44,266
Stiolto RespimatTiotropium Br/Olodaterol Hcl75$43,606
EliquisApixaban39$23,975
Spiriva RespimatTiotropium Bromide20$23,494
Spiriva HandihalerTiotropium Bromide25$21,331
SymbicortBudesonide/Formoterol Fumarate53$17,607
Advair HfaFluticasone Propion/Salmeterol27$16,822
Fluticasone-SalmeterolFluticasone Propion/Salmeterol101$15,759
XareltoRivaroxaban18$15,701
DuleraMometasone/Formoterol27$15,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta$205,212$444,427484 claims
Grifols USA, LLCProlastin C$1,032$189,19415 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$550,573$125,476177 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$20,416$67,10095 claims
PfizerEliquis$372,541$23,97539 claims
MerckDulera$464$15,14827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Rincon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →